• Edward A Bell and Geoffrey C Wall.
• College of Pharmacy and Health Sciences, Drake University, Des Moines, IA 50311-4505, USA. ed.bell@drake.edu
• Ann Pharmacother. 2004 Apr 1; 38 (4): 686-93.

ObjectiveTo review current guidelines on the treatment of functional constipation in pediatric patients, with an emphasis on the role of polyethylene glycol 3350 (PEG 3350).Data SourcesPrimary medical literature published in English was identified by MEDLINE search (1980-May 2003).Study Selection And Data ExtractionRecently published treatment guidelines relating to pediatric functional constipation and its pharmacotherapy are assessed and compared. Published trials evaluating PEG 3350 in pediatric subjects are discussed and their results applied to the clinical role and use of this new agent.Data SynthesisConstipation is a common disorder among children. A number of factors may play a role. A variety of medications are commonly used for this disorder, although few treatments have undergone evaluation by controlled clinical trials. Consensus guidelines recommend either osmotic laxatives, mineral oil, or their combination for maintenance treatment in concert with patient and parental education and behavioral training. PEG 3350 solution (MiraLax) has been shown in recent clinical studies to be an effective maintenance treatment for pediatric constipation.ConclusionsPEG 3350 is an effective and well-tolerated treatment choice for pediatric constipation, especially as an adjunct to education and behavioral training. PEG 3350 is an option for children with constipation who have failed or are intolerant of other pharmacotherapies.

16 keywords...

hide…